

# Helmout Modjtahedi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5033606/publications.pdf>

Version: 2024-02-01

57  
papers

1,723  
citations

331538

21  
h-index

289141

40  
g-index

60  
all docs

60  
docs citations

60  
times ranked

2730  
citing authors

#	ARTICLE	IF	CITATIONS
1	Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors. <i>Gene</i> , 2022, 813, 146101.	1.0	4
2	HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 638.	1.7	6
3	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. <i>Cancers</i> , 2021, 13, 1781.	1.7	17
4	Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients. <i>Scientific Reports</i> , 2021, 11, 8833.	1.6	7
5	Cytokine/Chemokine Release Patterns and Transcriptomic Profiles of LPS/IFN $\gamma$ -Activated Human Macrophages Differentiated with Heat-Killed <i>Mycobacterium obuense</i> , M-CSF, or GM-CSF. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7214.	1.8	3
6	Aberrant DNA methylation of <i>PTPRG</i> as one possible mechanism of its underexpression in CML patients in the State of Qatar. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2020, 8, e1319.	0.6	8
7	Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin $\alpha 3$ in human pancreatic cancer. <i>Scientific Reports</i> , 2020, 10, 537.	1.6	4
8	Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer. <i>Oncology Reports</i> , 2020, 44, 2581-2594.	1.2	7
9	Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer. <i>Oncotarget</i> , 2019, 10, 1704-1715.	0.8	17
10	Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 89-94.	1.9	28
11	Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer. <i>Oncotarget</i> , 2018, 9, 19662-19674.	0.8	11
12	Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 19994-20007.	0.8	10
13	Construction of a Recombinant Phage-vaccine Capable of Reducing the Growth Rate of an Established LL2 Tumor Model. <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2018, 17, 240-249.	0.3	2
14	Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines. <i>Scientific Reports</i> , 2017, 7, 3964.	1.6	57
15	A novel recombinant anti-epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model. <i>Microbiology and Immunology</i> , 2017, 61, 531-538.	0.7	3
16	Immunomodulatory effects of heat-killed <i>Mycobacterium obuense</i> on human blood dendritic cells. <i>Innate Immunity</i> , 2017, 23, 592-605.	1.1	13
17	Inhibitory Effects of Culinary Herbs and Spices on the Growth of HCA-7 Colorectal Cancer Cells and Their COX-2 Expression. <i>Nutrients</i> , 2017, 9, 1051.	1.7	16
18	Defining Genome-Wide Expression and Phenotypic Contextual Cues in Macrophages Generated by Granulocyte/Macrophage Colony-Stimulating Factor, Macrophage Colony-Stimulating Factor, and Heat-Killed <i>Mycobacteria</i> . <i>Frontiers in Immunology</i> , 2017, 8, 1253.	2.2	7

#	ARTICLE	IF	CITATIONS
19	The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. <i>Oncotarget</i> , 2017, 8, 7666-7677.	0.8	18
20	Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. <i>International Journal of Oncology</i> , 2016, 49, 1825-1838.	1.4	26
21	Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. <i>International Journal of Oncology</i> , 2016, 48, 908-918.	1.4	25
22	Novel Molecular Findings in Protein Tyrosine Phosphatase Receptor Gamma (PTPRG) Among Chronic Myelocytic Leukemia (CML) Patients Studied By Next Generation Sequencing (NGS): A Pilot Study in Patients from the State of Qatar and Italy. <i>Blood</i> , 2016, 128, 5427-5427.	0.6	5
23	Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model. <i>Immunobiology</i> , 2015, 220, 1293-1304.	0.8	18
24	Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers. <i>British Journal of Cancer</i> , 2015, 113, 1010-1019.	2.9	22
25	Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope. <i>Immunopharmacology and Immunotoxicology</i> , 2014, 36, 309-315.	1.1	10
26	GA201: A Novel Humanized and Glycoengineered Anti-EGFR Antibody Letter. <i>Clinical Cancer Research</i> , 2014, 20, 1053-1054.	3.2	0
27	A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2014, 387, 505-521.	1.4	97
28	Co-Expression of HER Family Members in Patients with Dukes <sup>™</sup> C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival. <i>PLoS ONE</i> , 2014, 9, e91139.	1.1	15
29	Triple Tandem Mimotope Peptide of Epidermal Growth Factor Receptor Displaying on the Surface of M13 Phage Induces Anti-Tumor Response in Mice Tumor Model. <i>Iranian Journal of Biotechnology</i> , 2014, 12, 9-17.	0.3	3
30	Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells. <i>BMC Cancer</i> , 2013, 13, 41.	1.1	42
31	Resveratrol 3-O-glucuronide and resveratrol 4-O-glucuronide inhibit colon cancer cell growth: Evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest. <i>Molecular Nutrition and Food Research</i> , 2013, 57, 1708-1717.	1.5	54
32	Prognostic significance and targeting of HER family in colorectal cancer. <i>Frontiers in Bioscience - Landmark</i> , 2013, 18, 394.	3.0	23
33	Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10. <i>British Journal of Cancer</i> , 2012, 106, 883-888.	2.9	8
34	Therapeutic application of monoclonal antibodies in cancer: advances and challenges. <i>British Medical Bulletin</i> , 2012, 104, 41-59.	2.7	65
35	Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 2698.	3.0	17
36	Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. <i>International Journal of Oncology</i> , 2011, 39, 483-91.	1.4	20

#	ARTICLE	IF	CITATIONS
37	Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbit. <i>International Journal of Experimental Pathology</i> , 2010, 91, 224-234.	0.6	14
38	Amplification and expression of EGFR and ERBB2 in Wilms tumor. <i>Cancer Genetics and Cytogenetics</i> , 2009, 194, 88-95.	1.0	15
39	Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. <i>Anti-Cancer Drugs</i> , 2009, 20, 851-855.	0.7	152
40	Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. <i>International Journal of Oncology</i> , 2008, 33, 1107-13.	1.4	19
41	The epidermal growth factor receptors and their family of ligands: Their putative role in atherogenesis. <i>Atherosclerosis</i> , 2006, 186, 38-53.	0.4	163
42	Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents. <i>Biochemical Pharmacology</i> , 2006, 72, 941-948.	2.0	41
43	Responses of Human Colorectal Tumor Cells to Treatment with the Anti-EGFR Monoclonal Antibody ICR62 Used Alone and in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib. <i>Cancer Research</i> , 2006, 66, 7708-7715.	0.4	35
44	Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. <i>International Journal of Oncology</i> , 2006, 28, 329-35.	1.4	18
45	Molecular therapy of head and neck cancer. <i>Cancer and Metastasis Reviews</i> , 2005, 24, 129-146.	2.7	37
46	Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. <i>International Journal of Oncology</i> , 2005, 27, 317.	1.4	17
47	EGF mediates monocyte chemotaxis and macrophage proliferation and EGF receptor is expressed in atherosclerotic plaques. <i>Atherosclerosis</i> , 2004, 176, 21-26.	0.4	70
48	The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. <i>International Journal of Oncology</i> , 2004, 24, 241-8.	1.4	10
49	Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: A two-pronged attack for tumour therapy. <i>International Journal of Cancer</i> , 2003, 105, 273-280.	2.3	50
50	The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. <i>Cancer Letters</i> , 2002, 184, 223-230.	3.2	64
51	The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2002, 38, 627-640.	0.8	76
52	The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. <i>Pathology and Oncology Research</i> , 2002, 8, 252-256.	0.9	20
53	Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. <i>International Journal of Cancer</i> , 2000, 86, 307-317.	2.3	99
54	Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 155-161.	1.7	92

#	ARTICLE	IF	CITATIONS
55	Anti-EGFR monoclonal antibodies which act as EGF, TGF $\hat{\alpha}$ , HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours. , 1998, 75, 310-316.		32
56	Monoclonal Antibodies to the EGF Receptor Act as Betacellulin Antagonists. Biochemical and Biophysical Research Communications, 1996, 221, 625-630.	1.0	10
57	The Immune System. , 0, , 79-98.		0